Kidney Cancer Weekly

August 05, 2024

Videos

Peer-to-Peer Clinical Conversations

Durvalumab Plus Guadecitabine in Metastatic Kidney Cancer: Phase 1/2 Trial Results - Yousef Zakharia

Yousef Zakharia

Pedro Barata interviews Yousef Zakharia about a phase 1/2 trial combining durvalumab and guadecitabine in metastatic kidney cancer.

Functional Renal Imaging and Advances in Kidney Cancer Detection - Shankar Siva

Shankar Siva

Phillip Koo interviews Shankar Siva about advancements in functional renal imaging.

Beyond the Abstracts

Delphi Consensus on Stereotactic Ablative Radiotherapy for Oligometastatic and Oligoprogressive Renal Cell Carcinoma-A European Society for Radiotherapy and Oncology Study Endorsed by the European Association of Urology - Beyond the Abstract

Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9) - Beyond the Abstract

Conference Coverage

ASCO 2024: Preliminary Safety, Pharmacokinetics and Clinical Activity of DFF332, an Oral HIF2α Inhibitor, as Monotherapy in a Phase 1 Dose Escalation Study in Patients with Advanced Clear Cell Renal Cell Carcinoma.

AUA 2024: Renal Imaging for Active Surveillance: Have we Moved Past CT and MRI?

EAU 2024: Adjuvant Immunotherapy After pT3a F IV /N0 at Nephrectomy: Is That Real High-Risk for All? No

ASCO GU 2024: Subgroup Analyses of Efficacy Outcomes by Baseline Tumor Size in the Phase 3, Open-label CLEAR Trial

Articles

Editor Selected Abstracts and Commentaries

Renal Cancer

Identification of prognostic RNA editing profiles for clear cell renal carcinoma.

Germline Susceptibility to Renal Cell Carcinoma and Implications for Genetic Screening.

Upfront versus deferred cytoreductive nephrectomy following targeted or immunotherapy: a population-based propensity score-matched analysis of perioperative complications.

Myocarditis Following Pembrolizumab Plus Axitinib, and Belzutifan Plus Lenvatinib for Renal Cell Carcinoma: A Case Report.

Percutaneous ablation versus robotic‑assisted partial nephrectomy for cT1 renal cell carcinoma: an evidence-based analysis of comparative outcomes.

Radiodensities of skeletal muscle and visceral adipose tissues are prognostic factors in clear cell renal cell carcinoma.

Surgical and Oncological Outcomes of Level III-IV Versus Level I-II Inferior Vena Cava Thrombectomy: A Decennial Experience of a High-Volume European Referral Center.

Feasibility of a Smartphone Application for Education and Symptom Management of Patients With Renal Cell Carcinoma on Combined Tyrosine Kinase and Immune Checkpoint Inhibitors.

Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214.

Evaluating the Urinary Exosome microRNA Profile of von Hippel Lindau Syndrome Patients with Clear Cell Renal Cell Carcinoma.

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302).

Approaches to Treating High Risk and Advanced Renal Cell Carcinoma (RCC): Key Trial Data That Impacts Treatment Decisions in the Clinic.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2024 Digital Science Press, LLC